Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 9, 2018
Reporting Period: Fiscal quarter ended June 30, 2018 (Second Quarter 2018).
This filing serves to announce the Company's financial results for the second quarter of 2018. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the source text provided.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended June 30, 2018.
Guidance, Outlook, and Risks
The filing references a press release titled "Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update." While the title suggests the presence of a corporate update, the specific content regarding guidance, outlook, management commentary, risks, or unusual items is not included in the text of this Form 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (the attached press release) for specific revenue, net loss, and cash position figures for Q2 2018.
- Verify the "Corporate Update" section in the press release for any changes in clinical trial timelines or strategic direction.
- Confirm the Company's cash runway and burn rate as detailed in the full financial statements referenced in the press release.
- Check for any new risk factors or contingencies disclosed in the full press release text.